Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.
Lepletier A, Lutzky VP, Mittal D, Stannard K, Watkins TS, Ratnatunga CN, Smith C, McGuire HM, Kemp RA, Mukhopadhyay P, Waddell N, Smyth MJ, Dougall WC, Miles JJ. Lepletier A, et al. Among authors: dougall wc. Immunol Cell Biol. 2019 Feb;97(2):152-164. doi: 10.1111/imcb.12205. Epub 2018 Oct 17. Immunol Cell Biol. 2019. PMID: 30222899
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.
Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall VLJ, Liu C, Bettington ML, Takeda K, Long GV, Scolyer RA, Lan R, Siemers N, Korman A, Teng MWL, Johnston RJ, Dougall WC, Smyth MJ. Mittal D, et al. Among authors: dougall wc. Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20. Cancer Immunol Res. 2019. PMID: 30894377 Free PMC article.
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. Li XY, et al. Among authors: dougall wc. J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14. J Clin Invest. 2018. Retraction in: J Clin Invest. 2022 Mar 15;132(6):e159825. doi: 10.1172/JCI159825. PMID: 29757192 Free PMC article. Retracted.
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.
Harjunpää H, Blake SJ, Ahern E, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL. Harjunpää H, et al. Among authors: dougall wc. Oncoimmunology. 2018 Mar 26;7(7):e1445949. doi: 10.1080/2162402X.2018.1445949. eCollection 2018. Oncoimmunology. 2018. PMID: 29900061 Free PMC article.
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.
Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L, Smyth MJ. Guillerey C, et al. Among authors: dougall wc. Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9. Blood. 2018. PMID: 29986909 Free article.
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Wilmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL, Smyth MJ. Lepletier A, et al. Among authors: dougall wc. Clin Cancer Res. 2020 Jul 15;26(14):3671-3681. doi: 10.1158/1078-0432.CCR-19-3925. Epub 2020 Apr 28. Clin Cancer Res. 2020. PMID: 32345648
95 results